CK Life Sciences (HKG:0775) expects to post a loss attributable to shareholders of about HK$150 million for the six months ended June 30, compared with a profit of HK$1 million a year prior, a Thursday Hong Kong bourse filing said.
Shares of the company were down about 5% in Friday's recent trade.
The anticipated loss was mainly due to a planned increase in R&D investment, though overall operations remained stable during the period.
The interim results will be published on Aug. 12.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.